Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a rare and fatal complication after solid organ transplantation and hematopoietic stem cell transplantation. With the increase in the number of organ transplantation in recent years, the incidence of PTLD has also increased. It is currently believed that the main cause of PTLD is Epstein-Barr virus infection. PTLD contains a series of diseases with different clinical manifestations. Once diagnosed, the level of immunosuppression of patients should be reduced, and treatment with rituximab and chemotherapy should be given. This article aims to summarize the latest progress of PTLD treatment, for the purpose of providing new ideas for clinical management of PTLD patients, and improving the survival rate of PTLD patients.